Building on previous work led by Lara Veeken (doi.org/10.1093/infd...) who again contributed strongly to this work. Also @kchorton.bsky.social @aschwalbc.bsky.social , @danieljgrint.bsky.social and many others.

So I'm not convinced that these are 'unimportant' positives. More likely there is an opportunity to interrupt or even prevent further health and livelihood costs for the individual, and transmission for the community. But v much agree that there is a lot to figure out. 3/3

... given that progression rates for bac neg TB are around 10%/y. I also don't think we know yet what level of short and long term damage untreated (and sometimes self-resolved) aTB causes, and how much of that would be prevented by providing Rx in some form. Again, should know more soon. 2/3

Good question(s) - we ^think^ that around 50% of asymptomatic bac pos TB progress to full blown 'classic' disease (so 50% do not). But this is v hard to pin down for obvious reasons (we're trying). Two other points to consider is that we do treat HHC, and their risk of sTB is likely lower... 1/3

Excellent work by @LaraVeeken (www.linkedin.com/in/lara-veek...), @aschwalbc.bsky.social @kchorton.bsky.social and wider Bandung team id.linkedin.com/in/raspati-c...,
id.linkedin.com/in/bachti-al...

Thanks to co-authors on the #TB analysis @raclark18.bsky.social @cfmcquaid.bsky.social @alexandra-richards.bsky.social @reinhouben.bsky.social @richardwhite321.bsky.social and to John Stover at Avenir Health for pulling it all together.

@lshtm-tbmod.bsky.social @tb-lshtm.bsky.social